Durlobactam/Sulbactam sodium

度洛巴坦/舒巴坦钠

Report date: 2026/03/04 20:01:44
NMEQIDP

Base Information

Drug NameDurlobactam/Sulbactam sodium
Drug Alias Namebeta-lactam+ETX-2514Sulbactam/ETX 2514Sulbactam+ETX 2514ETX-2514+Sulbactambeta-lactam/ETX-2514 +[15] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBeta Lactamase inhibitorsBacterial beta-lactamase TEM inhibitors
TargetsBacterial beta-lactamase TEMBeta Lactamase
Therapy Area/IndicationsHospital-acquired pneumoniaAcinetobacter Baumannii InfectionsPneumonia, Ventilator-Associated +[7] 
Global Approved IndicationsHospital-acquired pneumoniaPneumonia, Ventilator-AssociatedPneumonia, Bacterial +[4] 
Approved Indications in ChinaHospital-acquired pneumoniaPneumonia, Ventilator-AssociatedPneumonia, Bacterial +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date2023/05/23
Country/TerritoryUnited StatesTaiwanThailand +[17] 
CombinationsYes DurlobactamSulbactam sodium
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEntasis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEntasis TherapeuticsInnoviva Specialty Therapeutics IncEntasis Therapeutics Inc
Inactive CompaniesInnoviva IncZai Lab (Shanghai) Co Ltd
Active IndicationsHospital-acquired pneumoniaAcinetobacter Baumannii InfectionsPneumonia, Ventilator-Associated +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG